Prolactinoma Treatment in Children and Adolescents (Age Under 18)

Children and adolescents under 18 with prolactinoma represent a distinct clinical population. Management in this age group follows evidence-based guidance developed specifically for pediatric and adolescent patients.

Clinical Scenario

This protocol applies to patients under 18 years of age diagnosed with prolactinoma. The pediatric and adolescent setting introduces specific considerations that distinguish this population from adults, requiring a tailored management approach.

Treatment Approach

The protocol for this age group includes surgical intervention as one of the management options. The full criteria, sequencing, and clinical decision points are detailed in the complete structured regimen.

Instant Access to Structured Evidence-Based Regimens

References

Dopamine agonist therapy is initiated at low doses (for example, 0.25 mg per week of cabergoline) (weak), with slow dose increases due to increased probability of adverse effects in children (strong).
Surgery should be considered in patients in whom vision is threatened, if severe neurological symptoms or CSF leakage is present, or if the mass is resistant to dopamine agonist therapy (strong).

DOI: 10.1038/s41574-023-00886-5 View source ↗